Meropenem (Meropenem) Patent Expiration, LOE Window & CMS Spending

Meropenem (Meropenem) by Hq Specialty: Off-Patent Genericized (AB Competition), 13 AB generics, $23.5M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHq Specialty
FDA Application & PathwayN215212 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors13
2024 CMS Total Public Spend$23.5M
2024 Medicare Part D Spend$17.5M
2024 Medicaid Spend$6.0M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 20.5% 2-yr change)